Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747437 | 0.82 | CES2 (0.34) | — | |
| SCHEMBL28481053 | 0.79 | RAPGEF4 (0.33) | RAPGEF4PDE2AAGBL2 | |
| SCHEMBL3410621 | 0.77 | NOTUM (0.46) | RAPGEF4PDE2ANOTUMCYP1A2MAPT | |
| SCHEMBL27982999 | 0.70 | CFTR (0.49) | NOTUMMAPT | |
| SCHEMBL29171609 | 0.70 | MAPT (0.43) | GAACYP1A2MAPTCYP2C19 | |
| SCHEMBL15063744 | 0.70 | — | — | |
| SCHEMBL297382 | 0.69 | — | — | |
| SCHEMBL596022 | 0.68 | RAPGEF4 (0.35) | RAPGEF4NOTUMMAPT | |
| SCHEMBL28040427 | 0.67 | RAPGEF4 (0.32) | RAPGEF4 | |
| SCHEMBL3702697 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | RAPGEF4 2975/4885PDE2A 984/4885AGBL2 3288/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | RAPGEF4 2975/4885PDE2A 984/4885AGBL2 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.